Fig. 4

TREM2 signaling prevents tumor progression in vivo. a Tumor volumes of WT and TREM2-TG mice. WT and TREM2-TG Mice were injected with B16-F10 cells subcutaneously after intraperitoneal injection of hu-Ig or TREM2-Ig. Tumor volumes were measured every 2 days. b The survival rate of tumor-bearing WT and TREM2-TG mice. Seven mice per group were used. Survival probabilities were analyzed using the Kaplan–Meier method. The significance of differences between groups assessed using the log-rank test. All statistical tests were two-sided, with *P < 0.05 taken to indicate significance. Significance of difference between samples was determined using two-way ANOVA analysis with Bonferroni posthoc test. WT + hu-Ig vs. TG + hu-Ig (**P < 0.01), WT + hu-Ig vs. WT + TREM2-Ig (*P < 0.05), and TG + hu-Ig vs. TG + TREM2-Ig (†P < 0.05, †††P < 0.001) were compared. c Representative photographs of lungs with metastatic colonies from mice of each group (top panel). Graph quantitates the total number of metastatic colonies in the lungs of each group treated with hu-Ig or TREM2-Ig (bottom panel). WT + hu-Ig vs. TG + hu-Ig (^#P < 0.01) WT + hu-Ig vs. WT + TREM2-Ig (***P < 0.05), and TG + hu-Ig vs. TG + TREM2-Ig (†††P < 0.001) were compared. Significance of difference between samples was determined using two-way ANOVA analysis with Bonferroni posthoc test